{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:15:03Z","timestamp":1761405303141,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.sleep.2013.02.001","type":"journal-article","created":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T16:47:44Z","timestamp":1362674864000},"page":"380-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Should patients with idiopathic rapid eye movement sleep behavior disorder receive preventive therapy for a neurodegenerative disease?"],"prefix":"10.1016","volume":"14","author":[{"given":"Nikola N.","family":"Trajanovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thien Thanh","family":"Dang-Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2013.02.001_b0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1474-4422(07)70246-6","article-title":"Calcium, ageing, and neuronal vulnerability in Parkinson\u2019s disease","volume":"6","author":"Surmeier","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2013.02.001_b0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.sleep.2013.02.001_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10565-006-0037-9","article-title":"A calcium channel blocker flunarizine attenuates the neurotoxic effects of iron","volume":"22","author":"Bostanci","year":"2006","journal-title":"Cell Biol Toxicol"},{"issue":"18","key":"10.1016\/j.sleep.2013.02.001_b0020","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1097\/WNR.0b013e3280115185","article-title":"Alpha-synuclein potentiates Ca2+ influx through voltage-dependent Ca2+ channels","volume":"17","author":"Adamczyk","year":"2006","journal-title":"NeuroReport"},{"issue":"6","key":"10.1016\/j.sleep.2013.02.001_b0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biopsych.2008.09.008","article-title":"Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of l-3,4 dihydroxyphenylalanine-induced dyskinesia","volume":"65","author":"Schuster","year":"2009","journal-title":"Biol Psychiatry"},{"issue":"16 Pt 2","key":"10.1016\/j.sleep.2013.02.001_b0030","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.sleep.2013.02.001_b0035","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2013.02.001_b0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and Parkinson\u2019s disease","volume":"175","author":"Pasternak","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.sleep.2013.02.001_b0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.22616","article-title":"Dihydropyridine calcium channel blockers and the progression of parkinsonism","volume":"71","author":"Marras","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2013.02.001_b0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and betablockers in relation to Parkinson\u2019s disease","volume":"13","author":"Ton","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.sleep.2013.02.001_b0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","article-title":"Neurological Disorders in Central Spain (NEDICES) Study Group. Antihypertensive agents and risk of Parkinson\u2019s disease, 7 essential tremor and dementia: a population-based prospective study (NEDICES)","volume":"33","author":"Louis","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"12","key":"10.1016\/j.sleep.2013.02.001_b0060","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/mds.23191","article-title":"Calcium channel blocker use and risk of Parkinson\u2019s disease","volume":"25","author":"Simon","year":"2010","journal-title":"Mov Disord"},{"issue":"3 pt 2","key":"10.1016\/j.sleep.2013.02.001_b0065","first-page":"II42","article-title":"Side effects of calcium channel blockers","volume":"11","author":"Russell","year":"1988","journal-title":"Hypertension"},{"issue":"Suppl. 3","key":"10.1016\/j.sleep.2013.02.001_b0070","first-page":"S319","article-title":"Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects","volume":"4","author":"Leonetti","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"10.1016\/j.sleep.2013.02.001_b0075","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mds.1120","article-title":"Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy","volume":"16","author":"Boeve","year":"2001","journal-title":"Mov Disord"},{"issue":"Suppl.","key":"10.1016\/j.sleep.2013.02.001_b0080","first-page":"A0794M","volume":"26","author":"Schenck","year":"2003","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.sleep.2013.02.001_b0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/WNL.0b013e3181ec7fac","article-title":"REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century","volume":"75","author":"Claassen","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2013.02.001_b0090","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.nbd.2011.10.003","article-title":"REM sleep behavior disorder: from dreams to neurodegeneration","volume":"46","author":"Postuma","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.sleep.2013.02.001_b0095","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1474-4422(10)70216-7","article-title":"Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid eye-movement sleep behaviour disorder: a prospective study","volume":"9","author":"Iranzo","year":"2010","journal-title":"Lancet Neurol"},{"issue":"24","key":"10.1016\/j.sleep.2013.02.001_b0100","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1212\/WNL.0b013e318278b658","article-title":"Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder","volume":"79","author":"Dang-Vu","year":"2012","journal-title":"Neurology"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945713000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945713000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:10:20Z","timestamp":1761405020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945713000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1389945713000580"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2013.02.001","relation":{},"ISSN":["1389-9457"],"issn-type":[{"type":"print","value":"1389-9457"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should patients with idiopathic rapid eye movement sleep behavior disorder receive preventive therapy for a neurodegenerative disease?","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2013.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}